Drug Discovery News and Research

RSS

The drug discovery process begins with recognizing a disease or clinical condition in which there is a lack of adequate medical treatment. Once a potential drug has been identified, pre-clinical research can begin. This process includes several stages; the first of which involves identifying and validating the prospective drug’s target through assay development, high throughput screening, hit identification and finally, lead optimization. Once the pre-clinical process is complete, the newly synthesized drug candidate is selected for future clinical development.

New CRISPR-based gene-editing tool could lead to better treatments for genetic disorders

A new CRISPR-based gene-editing tool has been developed which could lead to better treatments for patients with genetic disorders.

29 Sep 2023

Extending FDA-approved cancer drug indications requires high patient numbers, study finds

Number of patient participants needed for secondary approval of a new cancer drug.

29 Sep 2023

Aerosolized ACE2 neutralizes COVID-19 variants in lab and mice tests

Researchers from the University of Texas Southwestern have developed an aerosolized, mutated form of ACE2 that effectively neutralizes various SARS-CoV-2 variants in both cell cultures and mice. The study suggests that this modified ACE2 has promising preventive and therapeutic potential against COVID-19, especially with its easy aerosolized administration.

28 Sep 2023

Unlocking the code: BigRNA's deep learning model predicts RNA behavior

Researchers have developed BigRNA, a groundbreaking deep learning model capable of predicting RNA behavior, including tissue-specific expression and splicing, directly from genomic DNA sequences. The model excels in identifying pathogenic variants and could be a game-changer in the development of personalized RNA-based therapies for treating genetic diseases.

28 Sep 2023

Newly identified stem cell variants drive inflammation in cystic fibrosis patients

Two nationally recognized experts in cloning and stem cell science from the University of Houston, Wa Xian and Frank McKeon, are reporting that five lung stem cell variants dominate the lungs of patients with advanced cystic fibrosis (CF), and that these variants drive key aspects of CF pathology including inflammation, fibrosis and mucin secretion.

28 Sep 2023

Arrayed CRISPR Screening for Revolutionizing Target Discovery

In this interview conducted at SLAS EU 2023 in Brussels, Belgium, we spoke to Ulrike Kuenzel, Associate Director in the Functional Genomics department at AstraZeneca about the application of arrayed CRISPR screening for target identification and more.

From Society for Laboratory Automation and Screening (SLAS) 27 Sep 2023

SRI spins off a biosciences platform that accelerates drug discovery

SRI International announced today it is spinning off Synfini, a biosciences platform that accelerates the process by which pharmaceutical and other companies can design, synthesize, and bring to market molecules for drug development.

26 Sep 2023

Research presents new approach to identify therapeutic targets for human diseases associated with protein phase separation

Recent research demonstrates that protein phase separation (PPS) is widely present in cells and drives a variety of important biological functions.

25 Sep 2023

Machine learning speeds up virtual drug screening by 10-fold

Boosting virtual screening with machine learning allowed for a 10-fold time reduction in the processing of 1.56 billion drug-like molecules. Researchers from the University of Eastern Finland teamed up with industry and supercomputers to carry out one of the world's largest virtual drug screens.

22 Sep 2023

Weill Cornell Medicine receives NIH grant to lead a national contraceptive research center

Weill Cornell Medicine has received a three-year, nearly $6 million grant to lead one of three national contraceptive research centers.

21 Sep 2023

UQ researchers identify novel drug target to overcome cancer drug resistance

University of Queensland researchers have identified a novel drug target with the potential to overcome drug resistance and prevent tumor regrowth in cancer patients.

20 Sep 2023

Innovations in baculovirus–insect cell expression systems

The baculovirus–insect cell expression system—insect cells used in conjunction with the baculovirus expression vector system (BEVS)— remains a crucial technology for manufacturing large and complex proteins. This eukaryotic expression system offers inherent safety, ease of scale-up, flexible product design, and versatility for a broad range of proteins.

From Sino Biological Inc. 20 Sep 2023

LabGenius & Sanofi partnership yields positive results from AI antibody discovery platform

Today, LabGenius, a pioneer in the use of AI and machine learning for antibody discovery, releases new data from its antibody discovery platform following a multi-year collaboration with Sanofi.

From LabGenius 19 Sep 2023

Purdue researcher receives $1.38 million to fight against drug-resistant malaria in developing countries

A Purdue researcher is taking a giant leap forward in the fight against drug-resistant strains of malaria in developing countries.

15 Sep 2023

Nuvectis launches Phase 1a dose escalation clinical trial of new cancer drug

Clinical trials have begun for a drug candidate for hard-to-treat cancers, discovered at the University of Edinburgh and licensed by US biopharmaceutical company Nuvectis Pharma, Inc.

15 Sep 2023

ELRIG UK announces the formation of Engagement Strategy Work Group

The European Laboratory Research & Innovation Group (ELRIG) UK today announced the formation of its Engagement Strategy Work Group (ESWG). The group will provide strategic direction and guidance to help ensure the ELRIG community continues to grow and thrive.

15 Sep 2023

ELRIG UK Establishes Engagement Strategy Work Group

The European Laboratory Research & Innovation Group (ELRIG) UK today announced the formation of its Engagement Strategy Work Group (ESWG). The group aims to improve access to scientific programmes and grow ELRIG community

From ELRIG (UK) Ltd. 14 Sep 2023

Kuano closes £1.8M seed funding round to validate quantum simulation platform for drug discovery

Kuano, a drug discovery company combining quantum mechanics with AI to design the next generation of medicines, today announced the close of its £1.8M seed funding round, led by Mercia Ventures, and including ACF Investors, Ascension Ventures, o2h Ventures, Meltwind Advisory LLP, and other Angel investors.

From Kuano Ltd. 13 Sep 2023

Study reveals a new potential treatment approach for glioblastoma

The discovery of a previously unknown molecular target has inspired what may become a therapeutic breakthrough for people with glioblastoma, the most common and aggressive brain cancer.

11 Sep 2023

Low-molecular weight human interleukin-1β antagonist discovered

Researchers described the detection of a human interleukin-1β antagonist with low molecular weight that disrupts interactions with the interleukin-1 receptor type I receptor.

11 Sep 2023